作者
Dinesh Kumar Chellappan,Parteek Prasher,Vilashini Saravanan,Vanessa See Vern Yee,Wendy Chai Wen,Jia Wei Wong,Joon Kang Wong,Jing Tong Wong,Wai Yew Wan,Jestin Chellian,Nagashekhara Molugulu,A. Umamaheswari,Rania Ibrahim,Thiviya Darmarajan,Mayuren Candasamy,Pankaj Kumar Singh,Vijay Mishra,Madhur D. Shastri,Flavia C. Zacconi,Amlan Chakraborty,Meenu Mehta,Piyush Kumar Gupta,Harish Dureja,Monica Gulati,Sachin Kumar Singh,Gaurav Gupta,Niraj Kumar Jha,Brian G. Oliver,Kamal Dua
摘要
The challenges and difficulties associated with conventional drug delivery systems have led to the emergence of novel, advanced targeted drug delivery systems. Therapeutic drug delivery of proteins and peptides to the lungs is complicated owing to the large size and polar characteristics of the latter. Nevertheless, the pulmonary route has attracted great interest today among formulation scientists, as it has evolved into one of the important targeted drug delivery platforms for the delivery of peptides, and related compounds effectively to the lungs, primarily for the management and treatment of chronic lung diseases. In this review, we have discussed and summarized the current scenario and recent developments in targeted delivery of proteins and peptide-based drugs to the lungs. Moreover, we have also highlighted the advantages of pulmonary drug delivery over conventional drug delivery approaches for peptide-based drugs, in terms of efficacy, retention time and other important pharmacokinetic parameters. The review also highlights the future perspectives and the impact of targeted drug delivery on peptide-based drugs in the coming decade.